|
1
|
Gandhi S, Chen S, Hong L, Sun K, Gong E,
Li C, Yan LL and Schwalm JD: Effect of mobile health interventions
on the secondary prevention of cardiovascular disease: Systematic
review and meta-analysis. Can J Cardiol. 33:219–231.
2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huang Y, Cai X, Mai W, Li M and Hu Y:
Association between prediabetes and risk of cardiovascular disease
and all cause mortality: Systematic review and meta-analysis. BMJ.
355(i5953)2016.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Aziz M, Ali SS, Das S, Younus A, Malik R,
Latif MA, Humayun C, Anugula D, Abbas G, Salami J, et al:
Association of subjective and objective sleep duration as well as
sleep quality with non-invasive markers of sub-clinical
cardiovascular disease (CVD): A systematic review. J Atheroscler
Thromb. 24:208–226. 2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Sedighi M, Bahmani M, Asgary S, Beyranvand
F and Rafieian-Kopaei M: A review of plant-based compounds and
medicinal plants effective on atherosclerosis. J Res Med Sci.
22(30)2017.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Milic NM, Milin-Lazovic J, Weissgerber TL,
Trajkovic G, White WM and Garovic VD: Preclinical atherosclerosis
at the time of pre-eclamptic pregnancy and up to 10 years
postpartum: Systematic review and meta-analysis. Ultrasound Obstet
Gynecol. 49:110–115. 2017.PubMed/NCBI View Article : Google Scholar : (In En,
Spanish).
|
|
6
|
Zanoli L, Signorelli SS, Inserra G and
Castellino P: Subclinical atherosclerosis in patients with
inflammatory bowel diseases: A systematic review and meta-analysis.
Angiology. 68(463)2017.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Wu GC, Leng RX, Lu Q, Fan YG, Wang DG and
Ye DQ: Subclinical atherosclerosis in patients with inflammatory
bowel diseases: A systematic review and meta-analysis. Angiology.
68:447–461. 2017.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Usai MV, Bosiers MJ, Bisdas T, Torsello G,
Beropoulis E, Kasprzak B, Stachmann A and Stavroulakis K: Surgical
versus endovascular revascularization of subclavian artery
arteriosclerotic disease. J Cardiovasc Surg (Torino). 61:53–59.
2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Petrovski G, Gurusamy N and Das DK:
Resveratrol in cardiovascular health and disease. Ann N Y Acad Sci.
1215:22–33. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Li H, Yan Z, Zhu J, Yang J and He J:
Neuroprotective effects of resveratrol on ischemic injury mediated
by improving brain energy metabolism and alleviating oxidative
stress in rats. Neuropharmacology. 60:252–258. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Csiszar A: Anti-inflammatory effects of
resveratrol: Possible role in prevention of age-related
cardiovascular disease. Ann N Y Acad Sci. 1215:117–122.
2011.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wang H, Yang YJ, Qian HY, Zhang Q, Xu H
and Li JJ: Resveratrol in cardiovascular disease: What is known
from current research? Heart Fail Rev. 17:437–448. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Tomé-Carneiro J, Gonzálvez M, Larrosa M,
Yáñez-Gascón MJ, García-Almagro FJ, Ruiz-Ros JA, Tomás-Barberán FA,
García-Conesa MT and Espín JC: Resveratrol in primary and secondary
prevention of cardiovascular disease: A dietary and clinical
perspective. Ann NY Acad Sci. 1290:37–51. 2013.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Ruan BF, Lu XQ, Song J and Zhu HL:
Derivatives of resveratrol: Potential agents in prevention and
treatment of cardiovascular disease. Curr Med Chem. 19:4175–4183.
2012.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kattoor AJ, Pothineni NVK, Palagiri D and
Mehta JL: Oxidative stress in atherosclerosis. Curr Atheroscler
Rep. 19(42)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Niroumand S, Khajedaluee M,
Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G and
Dadgarmoghaddam M: Atherogenic index of plasma (AIP): A marker of
cardiovascular disease. Med J Islam Repub Iran.
29(240)2015.PubMed/NCBI
|
|
17
|
Henrot P, Foret J, Barnetche T, Lazaro E,
Duffau P, Seneschal J, Schaeverbeke T, Truchetet ME and Richez C:
Assessment of subclinical atherosclerosis in systemic lupus
erythematosus: A systematic review and meta-analysis. Joint Bone
Spine. 85:155–163. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yong WC, Sanguankeo A and Upala S:
Association between sarcoidosis, pulse wave velocity, and other
measures of subclinical atherosclerosis: A systematic review and
meta-analysis. Clin Rheumatol. 37:2825–2832. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Cho IJ, Ahn JY, Kim S, Choi MS and Ha TY:
Resveratrol attenuates the expression of HMG-CoA reductase mRNA in
hamsters. Biochem Biophys Res Commun. 367:190–194. 2008.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Liu G, Wang B, Zhang J, Jiang H and Liu F:
Total panax notoginsenosides prevent atherosclerosis in
apolipoprotein E-knockout mice: Role of downregulation of CD40 and
MMP-9 expression. J Ethnopharmacol. 126:350–354. 2009.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhang Y, Yang X, Bian F, Wu P, Xing S, Xu
G, Li W, Chi J, Ouyang C, Zheng T, et al: TNF-α promotes early
atherosclerosis by increasing transcytosis of LDL across
endothelial cells: Crosstalk between NF-κB and PPAR-γ. J Mol Cell
Cardiol. 72:85–94. 2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Piechota W: Correlation of
high-sensitivity CRP concentration with the extent of coronary
atherosclerosis in men with symptoms of ischemic heart disease. Pol
Merkur Lekarski. 18:511–515. 2005.PubMed/NCBI(In Polish).
|
|
23
|
Egorova MO: Increased serum level of the
acute inflammation phase parameter CRP and the high level of low
density lipoprotein cholesterol-factors of increased risk of
development of atherosclerosis and its complications (a literature
review). Klin Lab Diagn. 3-6:2002.PubMed/NCBI(In Russian).
|
|
24
|
Xing SS, Yang XY, Zheng T, Li WJ, Wu D,
Chi JY, Bian F, Bai XL, Wu GJ, Zhang YZ, et al: Salidroside
improves endothelial function and alleviates atherosclerosis by
activating a mitochondria-related AMPK/PI3K/Akt/eNOS pathway.
Vascul Pharmacol. 72:141–152. 2015.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kurdi A, Martinet W and De Meyer GRY: mTOR
inhibition and cardiovascular diseases: Dyslipidemia and
atherosclerosis. Transplantation. 102 (Suppl 1):S44–S46.
2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hu Q, Chai J, Liu L, Hou Y, Wang Y, Li B
and Yang H: Isolation, culture, and identification of canine
umbilical vein vascular endothelial cells. Zhongguo Xiu Fu Chong
Jian Wai Ke Za Zhi. 27:460–463. 2013.PubMed/NCBI(In Chinese).
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Song R, Li WQ, Dou JL, Li L, Hu Y, Guo J,
Lu D, Zhang G and Sun L: Resveratrol reduces inflammatory cytokines
via inhibiting nuclear factor-κB and mitogen-activated protein
kinase signal pathway in a rabbit atherosclerosis model. Zhonghua
Xin Xue Guan Bing Za Zhi. 41:866–869. 2013.PubMed/NCBI(In Chinese).
|
|
29
|
Pan W, Yu H, Huang S and Zhu P:
Resveratrol protects against TNF-α-induced injury in human
umbilical endothelial cells through promoting sirtuin-1-induced
repression of NF-KB and p38 MAPK. PLoS One.
11(e0147034)2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Verschuren L, Wielinga PY, van
Duyvenvoorde W, Tijani S, Toet K, van Ommen B, Kooistra T and
Kleemann R: A dietary mixture containing fish oil, resveratrol,
lycopene, catechins, and vitamins E and C reduces atherosclerosis
in transgenic mice. J Nutr. 141:863–869. 2011.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Kleemann R and Kooistra T: HMG-CoA
reductase inhibitors: Effects on chronic subacute inflammation and
onset of atherosclerosis induced by dietary cholesterol. Curr Drug
Targets Cardiovasc Haematol Disord. 5:441–453. 2005.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Doganer YC, Rohrer JE, Aydogan U, Agerter
DC, Cayci T and Barcin C: Atherosclerosis and liver function tests
in coronary angiography patients. West Indian Med J. 64:333–337.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Lin JH, Lin YF, Wang WJ, Lin YF, Chueh SJ,
Wu VC, Chu TS and Wu KD: Taiwan Primary Aldosteronism Investigation
(TAIPAI) Study Group. Plasma aldosterone concentration as a
determinant for statin use among middle-aged hypertensive patients
for atherosclerotic cardiovascular disease. J Clin Med.
7(382)2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Agarwal R and Agarwal P: Targeting
extracellular matrix remodeling in disease: Could resveratrol be a
potential candidate? Exp Biol Med (Maywood). 242:374–383.
2017.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Vilar-Pereira G, Carneiro VC, Mata-Santos
H, Vicentino ARR, Ramos IP, Giarola NLL, Feijó DF, Meyer-Fernandes
JR, Paula-Neto HA, Medei E, et al: Resveratrol reverses functional
chagas heart disease in mice. PLoS Pathog.
12(e1005947)2016.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Naia L, Rosenstock TR, Oliveira AM,
Oliveira-Sousa SI, Caldeira GL, Carmo C, Laço MN, Hayden MR,
Oliveira CR and Rego AC: Comparative mitochondrial-based protective
effects of resveratrol and nicotinamide in Huntington's disease
models. Mol Neurobiol. 54:5385–5399. 2017.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Silvello D, Narvaes LB, Albuquerque LC,
Forgiarini LF, Meurer L, Martinelli NC, Andrades ME, Clausell N,
dos Santos KG and Rohde LE: Serum levels and polymorphisms of
matrix metalloproteinases (MMPs) in carotid artery atherosclerosis:
Higher MMP-9 levels are associated with plaque vulnerability.
Biomarkers. 19:49–55. 2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Ishigaki Y, Kono S, Katagiri H, Oka Y and
Oikawa S: NTTP investigators. Elevation of HDL-C in response to
statin treatment is involved in the regression of carotid
atherosclerosis. J Atheroscler Thromb. 21:1055–1065.
2014.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Zhang Y, Wu NQ, Li S, Zhu CG, Guo YL, Qing
P, Gao Y, Li XL, Liu G, Dong Q and Li JJ: Non-HDL-C is a better
predictor for the severity of coronary atherosclerosis compared
with LDL-C. Heart Lung Circ. 25:975–981. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Mueller MA, Beutner F, Teupser D, Ceglarek
U and Thiery J: Prevention of atherosclerosis by the mTOR inhibitor
everolimus in LDLR-/-mice despite severe hypercholesterolemia.
Atherosclerosis. 198:39–48. 2008.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Lu XL, Zhao CH, Yao XL and Zhang H:
Quercetin attenuates high fructose feeding-induced atherosclerosis
by suppressing inflammation and apoptosis via ROS-regulated
PI3K/AKT signaling pathway. Biomed Pharmacother. 85:658–671.
2017.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Lv J, Yang L, Guo R, Shi Y, Zhang Z and Ye
J: Ox-LDL-induced microRNA-155 promotes autophagy in human
endothelial cells via repressing the Rheb/mTOR pathway. Cell
Physiol Biochem. 43:1436–1448. 2017.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Yao X, Yan C, Zhang L, Li Y and Wan Q:
LncRNA ENST00113 promotes proliferation, survival, and migration by
activating PI3K/Akt/mTOR signaling pathway in atherosclerosis.
Medicine (Baltimore). 97(e0473)2018.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Che J, Liang B, Zhang Y, Wang Y, Tang J
and Shi G: Kaempferol alleviates ox-LDL-induced apoptosis by
up-regulation of autophagy via inhibiting PI3K/Akt/mTOR pathway in
human endothelial cells. Cardiovasc Pathol. 31:57–62.
2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zhai C, Cheng J, Mujahid H, Wang H, Kong
J, Yin Y, Li J, Zhang Y, Ji X and Chen W: Selective inhibition of
PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage
and vulnerability of atherosclerotic plaque. PLoS One.
9(e90563)2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Tang F and Yang TL: MicroRNA-126
alleviates endothelial cells injury in atherosclerosis by restoring
autophagic flux via inhibiting of PI3K/Akt/mTOR pathway. Biochem
Biophys Res Commun. 495:1482–1489. 2018.PubMed/NCBI View Article : Google Scholar
|
